Rucaparib

(Rubraca®)

Rucaparib

Drug updated on 11/13/2023

Dosage FormTablet (oral; 200 mg, 250 mg, 300 mg)
Drug ClassPoly (ADP-ribose) polymerase (PARP) inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
  • For the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Rubraca.

Product Monograph / Prescribing Information

Document TitleYearSource
Rubraca (rucaparib) Prescribing Information.2022Clovis Oncology, Inc., Boulder, CO

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Efficacy and Safety of PARP Inhibitor Therapy in Advanced Ovarian Cancer: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials.2023Current Computer-Aided Drug Design
Comparative efficacy and safety of poly (ADP-ribose) polymerase inhibitors in patients with ovarian cancer: a systematic review and network meta-analysis.2022Frontiers in Oncology
The molecular mechanisms of actions, effects, and clinical implications of parp inhibitors in epithelial ovarian cancers: a systematic review.2022International Journal of Molecular Sciences
Comparative safety and tolerability of approved PARP inhibitors in cancer: a systematic review and network meta-analysis.2021Pharmacological Research
Comparative efficacy and safety of PARP inhibitors as maintenance therapy in platinum sensitive recurrent ovarian cancer: a network meta-analysis. 2021Frontiers in Oncology
Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.2021Frontiers in Oncology
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.2021Cancer
Comparison of poly (ADP-ribose) polymerase inhibitors (PARPis) as maintenance therapy for platinum-sensitive ovarian cancer: systematic review and network meta-analysis.2020Cancers
When and how to use parp inhibitors in prostate cancer: a systematic review of the literature with an update on on-going trials.2020European Urology Oncology
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer [ID1485].2019NICE
The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis.2018Critical Reviews in Oncology/Hematology

Clinical Practice Guidelines